Mentions in press and media 13
| Date | Title | Description |
| 30.08.2024 | EQT Infrastructure VI's Strategic Move: Shortening the Acceptance Period for OX2 AB | In the fast-paced world of finance, timing is everything. EQT Infrastructure VI, through its subsidiary Otello BidCo AB, has made a significant move by shortening the acceptance period for its public offer to acquire OX2 AB. This decision r... |
| 26.08.2024 | Publication of prospectus regarding Enzymatica’s rights issue | Publication of prospectus regarding Enzymatica’s rights issue Mon, Aug 26, 2024 12:29 CET Report this content NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG... |
| 03.08.2024 | Cyxone's Rights Issue: A Crucial Step Towards Innovation in Autoimmune Treatments | Cyxone AB, a Swedish biopharmaceutical company, is making waves in the healthcare sector. Today marks the beginning of a pivotal moment for the company: the subscription period for its rights issue. This initiative aims to raise up to SEK 2... |
| 01.08.2024 | The subscription period in Cyxone’s rights issue starts today | The subscription period in Cyxone’s rights issue starts today Thu, Aug 01, 2024 08:45 CET Report this content Today, 1 August 2024, the subscription period in Cyxone AB’s ("Cyxone" or "the Company") issue of shares (the ... |
| 31.07.2024 | Cyxone AB publishes investment memorandum | Cyxone AB publishes investment memorandum Wed, Jul 31, 2024 08:45 CET Report this content On 23 July 2024, the board of Cyxone AB (publ) ("Cyxone" or the "Company"), resolved to carry out a preferential rights issue of s... |
| 23.07.2024 | The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K | The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K Tue, Jul 23, 2024 08:30 CET Report this content The board of Cyxone AB (publ), corporate no. 559020-5471... |
| 19.02.2024 | Enzymatica publishes information memorandum about rights issue of shares | Enzymatica publishes information memorandum about rights issue of shares Mon, Feb 19, 2024 16:00 CET Report this content NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, RUSSIA, HONGKONG, ... |
| 09.05.2023 | Last day for subscription in Inhalation Sciences rights issue | Last day for subscription in Inhalation Sciences rights issue Tue, May 09, 2023 08:45 CET Report this content Today on May 9, 2023, is the last day for participation in Inhalation Sciences Sweden AB (publ)’s ("ISAB" or the "C... |
| 17.06.2022 | Dicot AB receives approximately 10 MSEK through the warrants of series TO 3 with a 90% subscription rate | Dicot AB receives approximately 10 MSEK through the warrants of series TO 3 with a 90% subscription rate Fri, Jun 17, 2022 18:35 CET Report this content Press release: Uppsala, June 17, 2022. Dicot AB (publ) (”Dicot” or the ”Company”) annou... |
| 13.06.2022 | Last day of trading with the warrants of series TO 3 in Dicot | Last day of trading with the warrants of series TO 3 in Dicot Mon, Jun 13, 2022 08:30 CET Report this content Press release: Uppsala, June 13, 2022. Today, June 13, 2022, is the last day of trading with the warrants of series TO 3. The subs... |
Show more